Supercomputer & Bioinformatics to Connect High Blood Pressure to Lower Alzheimer’s Risk

Seriously Alzheimer disease, is a progressive worst dementia, commonly says as loss of memory and intellectual abilities which interfere with daily life tasks. Its survival range is approximately four to 20 years. Dementia symptoms gradually worsen over a number of years, slowly kills a person and get worse overtime. In its early stages, the symptoms are like, memory loss is mild, but with late-stage brain that affects learning, the sixth leading cause of death in the United States.

There is a worldwide effort under way to find better ways to treat this disease, delay its onset, and prevent it from developing. According to recent study, researchers concluded, hypertension can increase the burden of ‘amyloid beta in the brain,’which contributes to plaque formation and alzheimer’s disease, they suggested that people with a ‘genetic predisposition’ to high blood pressure have a lower risk of developing Alzheimer’s disease.

According to the U.S. Government survey, Twenty nine percent of the population, or about 70 million, have high blood pressure, while one in every three individuals has hypertension have their condition under control. The United States Centers for Disease Control and Prevention, is spending more than $46 billion a year for medication and services for Alzheimer’s Disease.

The Alzheimer’s Disease ‘Genetics Consortium and the International Genomics’ of Alzheimer’s Project have provided the genetic data used by the study.

According to a new research published and discussed in the Brigham Young University, “It’s possible that medications used to treat high blood pressure also lowers the risk for Alzheimer’s, a progressive disease that affect a person’s memory and other cognitive functions.”

According to John Kauwe, Ph.D, co-author of the research and associate professor of Biology at the Brigham Young University in Utah, the “protective effect” may be coming from antihypertensive drugs, and not the condition itself. He underlined the fact that these drugs are already approved by the Food and Drug Administration, or FDA, “So we need to take a serious look at them.”

University of Cambridge Senior Investigator Scientist Robert Scott led the study, which used “Mendelian Randomization” to find if the risk factors (BMI, insulin resistance, blood pressure, cholesterol, diabetes) for Alzheimer’s had a causal impact. Mendelian randomization uses subjects’ genetics as a proxy for a randomized clinical trial.

Paul Crane, from the University of Washington said, “Our results are the opposite of what people might think. It may be that high blood pressure is protective, or it may be that something that people with high blood pressure are exposed to more often, such as antihypertensive medication, is protecting them from Alzheimer’s disease.”

The researchers arrived at the conclusion after collecting and analyzing genetic data of more than 17,000 individuals with Alzheimer’s and over 37,000 people who did not have the disease on a supercomputer at the university.

Using the university’s supercomputer, Kauwe and an undergraduate student used 32 data sets for analysis on the supercomputer. Robert Scott, a University of Cambridge senior investigator scientist who led the study, used a technique called “Mendelian randomization” to find if risk factors, such as Body Mass Index, insulin resistance, blood pressure, cholesterol and diabetes, had a causal impact on Alzheimer’s, the release said.

“This is to date the most authoritative paper looking at causal relationships between Alzheimer’s Disease and these potentially modifiable factors,” Kauwe said in the release. “In terms of the number of samples, it can’t get bigger at this point.”

Further, fighting between Alzheimer’s & Researchers continues….

–Sugandha Sharma